Immune response to varicella-zoster virus glycoproteins in guinea pigs infected with Oka varicella vaccine

Vaccine

Volumn 16, Issue 13, 1998, Pages 1263-1269

  Sato, Hitoshi ^a   Kageyama, Seiji ^a   Imakita, Masami ^b   Ida, Mitsuru ^a   Yamamura, Jun Ichi ^a   Kurokawa, Masahiko ^a   Shiraki, Kimiyasu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Delayed type hypersensitivity; Oka varicella vaccine; VZV glycoproteins

Indexed keywords

CHICKENPOX VACCINE; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHICKENPOX; DELAYED HYPERSENSITIVITY; FEMALE; GUINEA PIG; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS;

ANIMALS; CHICKENPOX VACCINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIGS; HERPESVIRUS 3, HUMAN; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; SKIN TESTS; SPLEEN; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS;

EID: 0032145741     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00035-8     Document Type: Article

References (48)

1. 1 Grose, C. and Giller, R. Varicella-zoster infection and immunization in the healthy and the immunocompromised hosts. Crit. Rev. Oncol. Hematol. 1988, 8, 27-64.
2. 2 Straus, S.E., Ostrove, J.M. and Inchauspe, G. et al. Varicellazoster virus infections: biology, natural history, treatment, and prevention. Ann. Inter. Med. 1988, 108, 221-237.
3. 3 Arvin, A. Varicella-zoster virus. In: Fields Virology (Eds Fields, B.N., Knipe, D.M., Howley, P.M. et al.). 3rd edn., Vol. 2, Lippincott-Raven, Philadelphia, New York, 1996, pp. 2547-2585.
4. 4 Takahashi, M., Hayakawa, Y., Shiraki, K., Yamanishi, K., Asano, Y. and Ozaki, T. Attenuation and laboratory markers of the Oka-strain varicella-zoster virus. Postgrad. Med. J. 1985, 4, 37-46.
5. 5 Gershon, A.A., LaRussa, P., Hardy, I., Steinberg, S. and Silverstein, S. Varicella vaccine: the American experience. J. Infect, Dis. 1992, 166, S63-S68.
6. 6 Baba, K., Yabuuchi, H., Takahashi, M. and Ogra, P.L. Increased incidence of herpes zoster in normal children infected with varicella zoster virus during infancy: community-based follow-up study. J. Pediatr. 1986, 108, 372-377.
7. 7 Dworsky, M., Whitley, R. and Alford, C. Herpes zoster in early infancy. Am. J. Dis. Child. 1980, 134, 233-235.
8. 8 Patterson, L.E., Butler, K.M. and Edwards, M.S. Clinical herpes zoster shortly following primary varicella in two HIV-infected children. Clin. Pediatr. 1989, 28, 354.
9. 9 Hayward, A. and Herberger, M. Lymphocytes responses to varicella-zoster virus in the elderly. J. Clin. Immunol. 1987, 7, 174-178.
10. 10 Hayward, A., Levin, M., Wolf, W., Angelova, G. and Gilden, D. Varicella-zoster virus-specific immunity after herpes zoster. J. Infect. Dis. 1991, 163, 873-875.
11. 11 Berger, R., Luescher, D. and Just, M. Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J. Infect. Dis. 1984, 149, 647.
12. 12 Watson, B., Rothstein, E. and Bernstein, H. et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J. Infect. Dis. 1995, 172, 217-219.
13. 13 Kamiya, H., Ihara, T. and Hattori, A. et al. Diagnostic skin test reactions with varicella virus antigen and clinical application of the test. J. Infect. Dis. 1977, 136, 784-788.
14. 14 Asano, Y., Shiraki, K., Takahashi, M., Nagai, H., Ozaki, T. and Yazaki, T. Soluble skin test antigen of varicella-zoster virus prepared from the fluid of infected cultures. J. Infect. Dis. 1981, 143, 684-692.
15. 15 LaRussa, P., Steinberg, S.P., Seeman, M.D. and Gershon, A.A. Determination of immunity to varicella-zoster virus by means of an intradermal skin test. J. Infect. Dis. 1985, 152, 869-875.
16. 16 Takahashi, M., Iketani, T. and Sasada, K. et al. Immunization of the elderly and patients with collagen vascular diseases with live varicella vaccine and use of varicella skin antigen. J. Infect. Dis. 1992, 166, S58-S62.
17. 17 Shiraki, K., Yamanishi, K. and Takahashi, M. Biologic and immunologic characterization of the soluble skin test antigen of varicella-zoster virus. J. Infect. Dis. 1984, 149, 501-504.
18. 18 Shiraki, K., Yamanishi, K., Takahashi, M. and Dohi, Y. Delayed-type hypersensitivity and in vitro lymphocyte response in guinea pigs immunized with a live varicella vaccine. Biken. J. 1984, 27, 19-22.
19. 19 Baba, K., Shiraki, K. and Kanesaki, T. et al. Specificity of skin test with varicella-zoster virus antigen in varicella-zoster and herpes simplex virus infections. J. Clin. Microbiol. 1987, 25, 2193-2196.
20. 20 Shiraki, K., Okuno, T., Yamanishi, K. and Takahashi, M. Polypeptides of varicella-zoster virus (VZV) and immunological relationship of VZV and herpes simplex virus. J. Gen. Virol. 1982, 61, 225-269.
21. 21 Diaz, P.S., Smith, S., Hunter, E. and Arvin, A.M. Immunity to whole varicella-zoster virus antigen and glycoproteins I and p170, relation to the immunizing regimen of live attenuated varicella vaccine. J. Infect. Dis. 1988, 158, 1245-1252.
22. 22 Giller, R.H., Winistorfer, S. and Grose, C. Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J. Infect. Dis. 1989, 160, 919-928.
23. 23 LaRussa, P.S., Gershon, A.A., Steinberg, S.P. and Chartrand, S.A. Antibodies to varicella-zoster virus glycoproteins I, II, and III in leukemic and healthy children. J. Infect. Dis. 1990, 162, 627-633.
24. 24 Brunell, P.A., Novelli, V.M., Keller, P.M. and Ellis, R.W. Antibodies to the three major glycoproteins of varicella-zoster virus, search for the relevant host immune response. J. Infect. Dis. 1987, 156, 430-435.
25. 25 Shiraki, K., Sato, H. and Yamamura, J. et al. Functions of purified gB, gE, gI, and gH, gL, and their sialyl residues in varicella-zoster virus function. Arch. Virol. 1997, 142, 2295-2301.
26. 26 Arvin, A.M. Cell-mediated immunity to varicella-zoster virus. J. Infect. Dis. 1992, 166, S35-S41.
27. 27 Grose, C. and Litwin, V. Immunology of the varicella-zoster virus glycoproteins. J. Infect. Dis. 1988, 157, 877-881.
28. 28 Shiraki, K. and Takahashi, M. Virus particles and glycoprotein excreted from cultured cells infected with varicella-zoster virus (VZV). J. Gen. Virol. 1982, 61, 271-275.
29. 29 Shiraki, K., Ochiai, H. and Matsui, S. et al. Processing of hepatitis B virus surface antigen expressed by recombinant Oka varicella vaccine virus. J. Gen. Virol. 1992, 73, 1401-1407.
30. 30 Shiraki, K. and Hyman, R.W. The immediate early proteins of varicella-zoster virus. Virology 1987, 156, 423-426.
31. 31 Okuno, T., Yamanishi, K., Shiraki, K. and Takahashi, M. Synthesis and processing of glycoproteins of varicella-zoster virus (VZV) as studied with monoclonal antibodies to VZV antigens. Virology 1983, 129, 357-368.
32. 32 Sugano, T., Matsumoto, Y., Miyamoto, C. and Masuho, Y. Hybridomas producing human monoclonal antibodies against varicella-zoster virus. Eur. J. Immunol. 1987, 17, 359-364.
33. 33 Shiraki, K., Ogino, T., Yamanishi, K. and Takahashi, M. Immunochemical characterization of pyrimidine kinase induced by varicella-zoster virus. J. Gen. Virol. 1985, 66, 221-229.
34. 34 Arvin, A.M., Solem, S.M., Koropchak, C.M., Kinney-Thomas, E. and Paryani, S.G. Humoral and cellular immunity to varicella-zoster virus glycoprotein gpl and to a non-glycosylated protein, p170, in the strain 2 guinea-pig. J. Gen. Virol. 1987, 68, 2449-2454.
35. 35 Bogger-Goren, S., Bernstein, J.M., Gershon, A.A. and Ogra, P.L. Mucosal cell-mediated immunity to varicella zoster virus, role in protection against disease. J. Pediatr. 1984, 105, 195-199.
36. 36 Sugano, T., Tomiyama, T. and Matsumoto, Y. et al. A human monoclonal antibody against varicella-zoster virus glycoprotein III. J. Gen. Virol. 1991, 72, 2065-2073.
37. 37 Grose, C. Glycoproteins encoded by varicella-zoster virus, biosynthesis, phosphorylation, and intracellular trafficking. Ann. Rev. Microbiol. 1990, 44, 59-80.
38. 38 Montalvo, E.A. and Grose, C. Neutralization epitope of varicella zoster virus on native viral glycoprotein gp118 (VZV glycoprotein gpIII). Virology 1986, 149, 230-241.
39. 39 Forghani, B., Dupuis, K. and Schmidt, N.J. Epitopes functional in neutralization of varicella-zoster virus. J. Clin. Microbiol. 1990, 28, 2500-2506.
40. 40 Cohen, J.I. and Straus, S.E. Varicella-zoster virus and its replication. In: Fields Virology (Eds Fields, B.N., Knipe, D.M., Howley, P.M. et al.). 3rd edn., Vol. 2, Lippincott-Raven, Philadelphia, New York, 1996, pp. 2525-2545.
41. 41 Duus, K.M., Hatfield, C. and Grose, C. Cell surface expression and fusion by the varicella-zoster virus gH, gL glycoprotein complex, analysis by laser scanning confocal microscopy. Virology 1995, 210, 429-440.
42. 42 Forghani, B., Ni, L. and Grose, C. Neutralization epitope of the varicella-zoster virus gH, gL glycoprotein complex. Virology 1994, 199, 458-462.
43. 43 Keller, P.M., Lonergan, K., Neff, B.J., Morton, D.A. and Ellis, R.W. Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J. Virol. Methods 1986, 14, 177-188.
44. 44 lto, M., Mizutani, K. and Kamiya, T. et al. Inhibition of varicella-zoster virus (VZV) glycoprotein expression by a human monoclonal antibody against VZV glycoprotein III. J. Infect. Dis. 1993, 168, 1256-1259.
45. 45 Keller, P.M., Davison, A.J., Lowe, R.S., Riemen, M.W. and Ellis, R.W. Identification and sequence of the gene encoding gpIII, a major glycoprotein of varicella-zoster virus. Virology 1987, 157, 526-533.
46. 46 Baba, K., Yabuuchi, H., Takahashi, M., Gershon, A.A. and Ogra, P.L. Seroepidemiologic behavior of varicella zoster virus infection in a semiclosed community after introduction of VZV vaccine. J. Pediatr. 1984, 105, 712-716.
47. 47 Abul, K.A., Kenneth, M.M. and Sher, A. Functional diversity of helper T lymphocytes. Nature 1996, 383, 787-793.
48. 48 Hata, S. Skin test with varicella-zoster virus antigen on herpes zoster patients. Arch. Dermatol. Res. 1980, 268, 65-70.